Associated Press reports citing expert opinions… “Reactions vary from person to person”
“High expectations for medicine can lead to disappointment”
AP reported on the 23rd (local time) that GLP-1 receptor agonist obesity treatments such as ‘Wegobee’ (ingredient name: semaglutide) and ‘Maunjaro’ (ingredient name: terzepatide) do not have a weight loss effect for one in five people. The news agency reported citing expert opinions.
According to the Associated Press, most obese patients who took Hugovina Maunjaro in clinical trials lost an average of 15 to 22 percent of their weight. However, 10-15% of clinical trial participants lost less than 5% of their body weight and were classified as ‘non-responders’.
However, experts pointed out that in a situation where millions of people are taking the drug, the non-responder rate could reach up to 20%. He warned that patients should not expect uniform effects from drugs.
Fatima Cody, an obesity specialist and professor at Stanford Massachusetts General Hospital (MGH), said, “It is important to explain that each person reacts differently.”
GLP-1 receptor agonists are substances with a structure similar to the GLP-1 hormone. GLP-1 hormone is a hormone secreted when food is consumed. It acts on pancreatic beta cells to increase insulin secretion and decrease glucagon secretion, producing effects such as lowering blood sugar. It also acts on the brain to suppress appetite and helps maintain a feeling of fullness by delaying the passage of food from the stomach.
It is said that differences in response to GLP-1 receptor agonist obesity treatment drugs may occur due to genetic, hormonal, and personal factors. Professor Stanford explained, “Illnesses such as sleep apnea and certain medications such as antidepressants, steroids, and birth control pills can interfere with the weight loss effect.”
Another expert expressed concern that patients may feel frustrated if the weight loss effect is less than expected. “High expectations can lead to disappointment,” said Catherine Saunders, a professor at Weill Cornell Medical College. “It can take a huge emotional toll.”
Experts emphasized that comprehensive analysis and appropriate treatment are important because drug reactions can be confirmed quickly.
Jody Dussey, a professor at Beth Israel Deaconess Medical Center (BIDMC), said, “There is a possibility that treatment with a different GLP-1 drug may be attempted or that the patient may respond better to an older drug,” adding, “It is not over if the drug does not respond. “I hope
Professor Saunders said, “Lifestyle changes such as diet, exercise, sleep, and stress management can have as big an impact as medication, so a comprehensive treatment approach is necessary.” He added, “Although prescriptions may not be effective, there are always other alternatives. “He said.
- I’m angry
- 0dog
- I recommend it
- dog
Hot news now
What are the potential side effects of GLP-1 receptor agonist drugs like Wegovi and Maunjaro in obesity treatment?
Interview: Exploring the Complexities of Obesity Treatments
Editor: Welcome to Time.news, where we delve into important health topics that affect millions of people around the world. Today, we’re joining forces with Professor Fatima Cody, an obesity specialist from Stanford Massachusetts General Hospital, to discuss recent findings on GLP-1 receptor agonist drugs like Wegovi and Maunjaro. Thank you for being here, Professor Cody.
Professor Cody: Thank you for having me. It’s a pleasure to discuss these important developments in obesity treatment.
Editor: The recent report from the Associated Press highlighted that around one in five patients does not experience the desired weight loss results from these medications. Can you explain why there is such variability in patient responses?
Professor Cody: Certainly. While clinical trials show an average weight loss of about 15% to 22% among participants taking drugs like Wegovi and Maunjaro, the reality is more nuanced. Several factors influence individual responses, such as genetic predispositions, hormonal differences, and even personal health issues. For example, conditions like sleep apnea or individuals taking certain medications like antidepressants can affect how these drugs work.
Editor: That sounds quite complex. With approximately 10-15% of patients classified as non-responders, how can we manage expectations around these treatments?
Professor Cody: That’s a critical point. It’s vital for healthcare providers to communicate that not everyone will have the same results. High expectations can lead to disappointment, which can have significant emotional repercussions. We need to have realistic discussions with patients about what they might expect and how differing reactions are completely normal.
Editor: Catherine Saunders, another expert in the field, mentioned the emotional toll that unmet expectations can take on patients. How can we better support individuals going through their weight loss journey?
Professor Cody: Support is essential. First, we need to encourage open communication between patients and their healthcare providers. Regular check-ins can help patients feel heard and understood. Additionally, offering behavioral support can be beneficial. This could include counseling or support groups where individuals can share experiences and strategies.
Editor: It’s interesting to note that behavioral factors play a significant role alongside biological responses. In light of this, how should clinicians approach treatment plans for their patients?
Professor Cody: A comprehensive analysis is crucial. Motivational interviewing can help uncover personal barriers to weight loss beyond just the medication itself. Each treatment plan should be customized, taking into consideration the individual’s health history, lifestyle, and personal goals. Collaboration is key.
Editor: It sounds like there’s still a lot we need to learn about the long-term success of these treatments. What are the next steps for researchers and healthcare professionals?
Professor Cody: Continued research is essential to fully understand the demographics and biological markers that define responders versus non-responders. Additionally, we must investigate alternative treatment options for those who do not respond to these medications, as well as explore integrative approaches that include diet, exercise, and behavioral therapy alongside pharmacological treatments.
Editor: Thank you, Professor Cody, for sharing your insights on this important topic. As the conversation around obesity treatments evolves, it’s clear that understanding individual differences will be crucial for patient success.
Professor Cody: Thank you for raising awareness of these critical issues. It’s important that we continue to support patients in their journeys toward better health.